- Thermo Fisher Scientific (TMO.US) shares are up about 4% in premarket trading today following the announcement of a strategic collaboration with OpenAI.
- This is yet another example of a company outside the traditional technology sector announcing a partnership with OpenAI in an effort to be seen by investors as a beneficiary of the AI revolution.
- Thermo Fisher Scientific (TMO.US) shares are up about 4% in premarket trading today following the announcement of a strategic collaboration with OpenAI.
- This is yet another example of a company outside the traditional technology sector announcing a partnership with OpenAI in an effort to be seen by investors as a beneficiary of the AI revolution.
Thermo Fisher Scientific (TMO.US) shares are up about 4% in premarket trading today following the announcement of a strategic collaboration with OpenAI. The company is implementing artificial intelligence solutions in key areas of its business, from clinical research and customer service to the Accelerator™ Drug Development platform and internal ChatGPT Enterprise implementations, with the aim of reducing the time to market for new drugs, managing innovation more effectively, and making better use of resources.
This is another example of a company outside the traditional technology sector announcing a partnership with OpenAI in an effort to be seen by investors as a beneficiary of the AI revolution that is driving the valuations of giants such as Nvidia, Microsoft, and Alphabet. The market clearly rewards any attempts to implement AI-based solutions: there is an automatic narrative about the possibility of repeating the success of technology companies whose shares have been gaining for months thanks to the AI boom. Hence today's positive reaction to TMO's stock price – investors see an opportunity for other sectors to jump on the fast-moving AI technology bandwagon, seeking to replicate the success of companies that have been key beneficiaries of this transformation for some time.
Just before the opening of Wall Street, the company's shares are up 4% and testing the recent local highs from October.
Source: xStation
Stock of the Week - Lam Research Corp (16.10.2025)
Salesforce surges 8% amid positive long-term revenue forecast📈
DE40: Europe moves sideways, Nestle gains
Nestlé: Steady Growth and Ambitious Restructuring Drive Share Price Surge
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
